What exactly did William Blair and BMO do on March 9, 2026 regarding ABBV analyst rating?

Both William Blair and BMO Capital maintained an Outperform rating on AbbVie Inc. (ABBV) on **March 9, 2026**. Neither firm issued a new price target; both reiterated positive views tied to competitive products and diversification potential.

Does a maintained Outperform mean AbbVie is a buy for investors?

A maintained Outperform signals analysts expect AbbVie to outperform peers, but it is not a fresh buy trigger. Investors should weigh the ABBV analyst rating with valuation, pipeline updates, competitive risks, and personal time horizon before acting.

Were any price targets published with these ABBV analyst rating notes?

No new price targets were published in the William Blair or BMO Capital notes on **March 9, 2026**. The lack of new targets means the comments functioned as reaffirmations rather than valuation resets.

How does Meyka AI view ABBV after these ratings?

Meyka AI rates **ABBV with a grade of B+**, reflecting relative strength versus benchmarks, sector positioning, growth metrics, and analyst consensus. This grade is informational and not investment advice; use it alongside fundamental analysis.

Analyst Ratings

William Blair and BMO Maintain Outperform on AbbVie Inc. (ABBV) March 2026

ByDanny Kontos March 10, 2026

On March 9, 2026, William Blair and BMO Capital each maintained an Outperform rating on AbbVie Inc. (ABBV). The ABBV analyst rating shows continued conviction from two major firms that AbbVie can expand beyond its core Immunology & Inflammation franchise. Both actions were reiterations rather than upgrades or downgrades, and neither firm published a new price target in these notes. The market reacted modestly, with intraday moves of 0.33% ($0.75) and 1.4% ($3.13) tied to each bulletin, respectively, signaling a steady, not seismic, investor response.